Limei Poon

Limei Poon

Auto-generated profile, based on publicly available information

Limei Poon

Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2020 in Journal of Medical Economics
Verified
Journal Article
Closed access
BCBoon Piang Cher
Boon Piang Cher
KGKar Yee Gan
Kar Yee Gan
MAMohamed Ismail Abdul Aziz
Mohamed Ismail Abdul Aziz
LLLiang Lin
Liang Lin
WHWilliam Ying Khee Hwang
William Ying Khee Hwang
KNKwong Ng
Kwong Ng
Background: Patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) have limited treatment options and poor prognoses. Tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy has shown early promise in improving survival outcomes, but at a high upfront cost. This study evaluated the cost-effectiveness of tisagenlecleucel versus salvage chemotherapy for treating patients with r/r DLBCL who have failed at least 2 lines of systemic therapies. Methods: A hybrid decision tree and three-state partitioned survival model (progression-free (PF), progressive disease and death) was developed from the Singapore healthcare payer perspective. Survival curves from JULIET trial and CORAL-1 extension study were extrapolated beyond trial period over a 15-year time horizon to estimate the underlying progression-free survival and overall survival parametric distributions for both arms. Health state utilities were retrieved from the literature, and direct costs were sourced from public healthcare institutions in Singapore. One-way probabilistic sensitivity analyses and scenario analyses were conducted to explore the impact of uncertainties and assumptions on cost-effectiveness results. Results: Compared with salvage chemotherapy, tisagenlecleucel was associated with a base-case incremental cost-effectiveness ratio (ICER) US$508,530 (S$686,516) per quality adjusted life year (QALY) gained and US$320,200 (S$432,269) per life year (LY) gained. One-way sensitivity analysis showed the ICER was most sensitive to time horizon, PF utility and cost of tisagenlecleucel. Scenario analyses confirmed that the ICERs remained high under favorable assumptions and substantial price reduction was required to reduce the ICER. Conclusions: Our analysis showed tisagenlecleucel use in r/r DLBCL patients who failed at least 2 prior lines of systemic therapies was associated with exceedingly high ICER, which is unlikely to represent good use of healthcare resources. Comparative clinical evidence from the ongoing trials might provide more insight into future evaluations.

25 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
LGLouis-Pierre Girard
Louis-Pierre Girard
CSCinnie Yentia Soekojo
Cinnie Yentia Soekojo
MOMelissa Gaik Ming Ooi
Melissa Gaik Ming Ooi
LPLi Mei Poon
Li Mei Poon
WCWee Joo Chng
Wee Joo Chng
SMSanjay De Mel
Sanjay De Mel
Monoclonal paraproteinaemia is an increasingly common reason for referral to haematology services. Paraproteinaemias may be associated with life-threatening haematologic malignancies but can also be an incidental finding requiring only observation. Immunoglobulin M (IgM) paraproteinaemias comprise 15–20% of monoclonal proteins but pose unique clinical challenges. IgM paraproteins are more commonly associated with lymphoplasmacytic lymphoma than multiple myeloma and can occur in a variety of other mature B-cell neoplasms. The large molecular weight of the IgM multimer leads to a spectrum of clinical manifestations more commonly seen with IgM paraproteins than others. The differential diagnosis of B-cell and plasma cell dyscrasias associated with IgM gammopathies can be challenging. Although the discovery of MYD88 L265P and other mutations has shed light on the molecular biology of IgM paraproteinaemias, clinical and histopathologic findings still play a vital role in the diagnostic process. IgM secreting clones are also associated with a number of “monoclonal gammopathy of clinical significance” entities. These disorders pose a novel challenge from both a diagnostic and therapeutic perspective. In this review we provide a clinical overview of IgM paraproteinaemias while discussing the key advances which may affect how we manage these patients in the future.

18 April 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MHMichal Marek Hoppe
Michal Marek Hoppe
PJPatrick Jaynes
Patrick Jaynes
FSFan Shuangyi
Fan Shuangyi
YPYanfen Peng
Yanfen Peng
SSShruti Sridhar
Shruti Sridhar
AJAnand D. Jeyasekharan
Anand D. Jeyasekharan
Cancers often overexpress multiple clinically relevant oncogenes, but it is not known if combinations of oncogenes in cellular subpopulations within a cancer influence clinical outcomes. Using quantitative multispectral imaging of the prognostically relevant oncogenes MYC, BCL2, and BCL6 in diffuse large B-cell lymphoma (DLBCL), we show that the percentage of cells with a unique combination MYC+BCL2+BCL6− (M+2+6−) consistently predicts survival across four independent cohorts (n = 449), an effect not observed with other combinations including M+2+6+. We show that the M+2+6− percentage can be mathematically derived from quantitative measurements of the individual oncogenes and correlates with survival in IHC (n = 316) and gene expression (n = 2,521) datasets. Comparative bulk/single-cell transcriptomic analyses of DLBCL samples and MYC/BCL2/BCL6-transformed primary B cells identify molecular features, including cyclin D2 and PI3K/AKT as candidate regulators of M+2+6− unfavorable biology. Similar analyses evaluating oncogenic combinations at single-cell resolution in other cancers may facilitate an understanding of cancer evolution and therapy resistance. Significance: Using single-cell–resolved multiplexed imaging, we show that selected subpopulations of cells expressing specific combinations of oncogenes influence clinical outcomes in lymphoma. We describe a probabilistic metric for the estimation of cellular oncogenic coexpression from IHC or bulk transcriptomes, with possible implications for prognostication and therapeutic target discovery in cancer. This article is highlighted in the In This Issue feature, p. 1027

22 April 2015 in Current Hematologic Malignancy Reports
Verified
Journal Article
Closed access
PDF file
PKPartow Kebriaei
Partow Kebriaei
MPMichelle Limei Poon
Michelle Limei Poon

1 July 2020 in The Breast Journal
Verified
Journal Article
Closed access
PDF file
TTTze Yang Vincent Tiong
Tze Yang Vincent Tiong
SASarah M. Alsannaa
Sarah M. Alsannaa
GSGwyneth Soon
Gwyneth Soon
LPLimei Michelle Poon
Limei Michelle Poon
YGYong Geng Goh
Yong Geng Goh
Click on the article title to read more.

5 March 2024 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
LGL. Girard
L. Girard
YKY. J. Koh
Y. J. Koh
LKL. P. Koh
L. P. Koh
YCY. L. Chee
Y. L. Chee
HCH. L. Chan
H. L. Chan
MSM. Samuel
M. Samuel